Allergan Plc is no longer looking at selling its women’s health business, Chief Executive Officer Brent Saunders said on Tuesday.
“For Women’s Health, we have concluded that the highest value proposition for this business at this time is to continue managing it and optimizing it,” Saunders said.
Saunders also said the company’s anti-infectives business will “more likely than not” be sold over the near term.
The company had said in May it was looking to sell both its women’s health and infectious disease units following a review of its businesses.
By Tamara Mathias
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.